Stacey Carlton, MD
Family Medicine · Crossville, TNNPI 1619976941
Payments from drug & device makers
Across 162 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$639
- Bausch Health US, LLC$287
- AbbVie$283
- Pfizer$196
- Merck$182
- Novo Nordisk$156
- plus $854 from 21 others
What the payments were for
- Food & beverage$2,596100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 35 | $639 |
| Bausch Health US, LLC | 20 | $287 |
| AbbVie(2 entities) | 16 | $283 |
| Pfizer | 15 | $196 |
| Merck | 10 | $182 |
| Novo Nordisk | 8 | $156 |
| Lilly USA, LLC | 10 | $150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $149 |
| Bayer | 7 | $106 |
| Novartis | 4 | $79 |
| Boehringer Ingelheim | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Corcept Therapeutics | 1 | $25 |
| Abbott | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| AstraZeneca | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $11 |
How this compares
$2,596 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 41 | $1,168,258 |
| OzempicSemaglutide | 32 | $44,173 |
| MounjaroTirzepatide | 31 | $40,718 |
| Repatha SureclickEvolocumab | 36 | $35,516 |
| XareltoRivaroxaban | 38 | $27,317 |
| EliquisApixaban | 21 | $23,090 |
| VraylarCariprazine Hcl | 14 | $19,671 |
| JardianceEmpagliflozin | 18 | $19,511 |
| EntrestoSacubitril/Valsartan | 17 | $17,033 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $15,457 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $12,685 |
| LantusInsulin Glargine,hum.Rec.Anlog | 28 | $11,504 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,747 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $9,212 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $9,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $639 | $1,168,25841 claims |
| Novo NordiskOzempic | $156 | $44,17332 claims |
| Lilly USA, LLCMounjaro | $150 | $40,71831 claims |
| Boehringer IngelheimJardiance, Glyxambi | $59 | $28,72330 claims |
| PfizerEliquis | $196 | $23,09021 claims |
| AbbVieVraylar | $283 | $19,67114 claims |
| NovartisEntresto | $79 | $17,03317 claims |
| Sanofi-aventis U.S. LLCLantus | $21 | $11,50428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Crossville
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.